A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2

Vaccine. 2008 Apr 16;26(17):2092-9. doi: 10.1016/j.vaccine.2008.02.034. Epub 2008 Mar 7.

Abstract

Enterohemorrhagic Escherichia coli (EHEC) produces Stx1 and Stx2 causing severe diseases. Their B-subunits (StxBs) exhibit low immunogenicity and the anti-StxB antibodies neutralizing both Stxs has not been prepared yet. By intranasal vaccination with His-tagged-StxB (Stx1B-His or Stx2B-His) plus a mutant heat-labile enterotoxin (mLT) in mice, their serum and lung fluid reacted with appropriate StxB. Mice vaccinated with Stx2B-His plus mLT had antibodies reacting Stx1B and showed the resistance to toxemia of Stx1 and Stx2. This is the first demonstration to get anti-Stx2B serum neutralizing both Stxs. These suggest that the nasal vaccination with Stx2B-His and mLT is effective for preventing toxemias by EHEC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intranasal
  • Animals
  • Antibodies, Bacterial / blood
  • Antibodies, Bacterial / immunology
  • Bacterial Vaccines / administration & dosage*
  • Bacterial Vaccines / immunology
  • Escherichia coli Infections / immunology
  • Escherichia coli Infections / prevention & control*
  • Escherichia coli Vaccines / immunology*
  • Lung / immunology
  • Mice
  • Shiga Toxin 1 / immunology*
  • Shiga Toxin 2 / immunology*
  • Vaccines, Subunit / administration & dosage
  • Vaccines, Subunit / immunology

Substances

  • Antibodies, Bacterial
  • Bacterial Vaccines
  • Escherichia coli Vaccines
  • Shiga Toxin 1
  • Shiga Toxin 2
  • Vaccines, Subunit